Hemispherx Biopharma, Inc.
(NYSE Amex Equities : HEB)

( )
HEB PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Loading HEB News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
1.30%83.341.8%$745.39m
BIIBBiogen Inc.
1.17%241.711.0%$581.03m
CELGCelgene Corporation
-0.30%98.511.2%$467.26m
AMGNAmgen Inc.
1.37%152.151.0%$450.08m
REGNRegeneron Pharmaceuticals, Inc.
0.39%349.233.1%$325.50m
ALXNAlexion Pharmaceuticals, Inc.
2.27%116.762.5%$311.51m
ILMNIllumina, Inc.
1.97%140.294.9%$169.60m
TSROTESARO, Inc.
8.59%84.0515.8%$143.75m
VRTXVertex Pharmaceuticals Incorporated
1.20%86.022.6%$133.88m
MDVNMedivation, Inc.
-1.07%60.302.8%$132.96m
BMRNBioMarin Pharmaceutical Inc.
-0.73%77.804.0%$128.97m
AAgilent Technologies, Inc.
1.35%44.351.0%$104.36m
SRPTSarepta Therapeutics, Inc.
2.20%19.0749.4%$104.18m
EXASExact Sciences Corporation
8.50%12.2521.4%$102.22m
ACADACADIA Pharmaceuticals Inc.
0.25%32.4619.6%$95.68m

Company Profile

Hemispherx Biopharma, Inc. is a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and the experimental immunotherapeutic/antiviral Ampligen. Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. Ampligen includes application as a treatment for Chronic Fatigue Syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Philadelphia, PA.